ClinicalTrials.gg
Active, not recruitingNCT07742852ASKC200Updated Aug 3, 2026

ASKC200 for Knee Osteoarthritis Pain

A Phase 2 interventional study of 5% ASKC200 and 1% Diclofenac Diethylamine Emulgel in Osteoarthritis (OA) of the Knee and Pain, sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd. (part of Beijing Aosaikang Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Sep 2025, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 74 studies in Osteoarthritis with a site in China — 23 open to participants now, 28 under way, 2 of them phase 3. Osteoarthritis · China.

Enrollment
22nd of 53
175 · median 139
Started
2025
with 14 others
Phase 2
4 of 74
1 open now
Primary completion
2026-04
later than 6 of 27 live
Registered
72nd of 74
by date

Among the 74 studies in Osteoarthritis with a site in China, this one is the 22nd largest by enrollment of the 53 interventional ones that give a count, is one of 15 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 6 of the 27 other live ones, and was the 72nd registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

23 of the 74 studies in Osteoarthritis with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Osteoarthritis with a site in China, or all of them as a file.
02

Study summary

This is a Phase II clinical trial designed to evaluate the efficacy and safety of ASKC200 Lotion in patients with knee osteoarthritis (KOA) pain. A total of 175 eligible patients will be randomly assigned to three groups at a 1:2:2:2 ratio: the experimental group1 (treated with 1% ASKC200 Lotion), the experimental group 2(treated with 5% ASKC200 Lotion), the active control group (treated with Diclofenac Diethylamine Emulgel), and the placebo group (treated with matching placebos).

03

Conditions studied

  • Osteoarthritis (OA) of the Knee
  • Pain
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following criteria:

  1. Provide signed before undergoing any examinations or assessments, and understand and comply with the study requirements;
  2. Aged 40 to 80 years (inclusive) at the time of signing the informed consent, male or female;
  3. Diagnosed with primary knee osteoarthritis based on clinical and radiological examinations;
  4. History of knee osteoarthritis pain lasting ≥ 6 months;
  5. Within 3 months prior to dosing, X-ray of the tibiofemoral joint shows Kellgren-Lawrence Grade II or III in the target knee, with the contralateral knee grade not higher than the target side;
  6. Before the first dose, the weekly average of the daily mean pain NRS score in the target knee is ≥ 4 and \< 8, and the weekly average of the daily mean pain NRS score in the contralateral knee is \< 4;
  7. Before the first dose, the WOMAC pain scale score for the target knee is ≥ 20, and the WOMAC pain scale score for the contralateral knee is \< 20;
  8. Willing to discontinue the use of non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and other analgesics, and to use only study-provided acetaminophen as rescue medication for knee osteoarthritis pain during the study period;
  9. (BMI) ≤ 40.0 kg/m²;
  10. Male and female subjects of agree to voluntarily adopt effective measures and have no plans for pregnancy, egg donation, or sperm donation from the screening period through 3 months after the last dose. Female subjects of childbearing potential must have a negative pregnancy test before the first use of the study drug.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the following criteria:

  1. Secondary arthritis due to other causes (e.g., psoriasis, ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, etc.);
  2. The target knee has other conditions that may affect the function and pain assessment of the target knee (e.g., fractures, osteonecrosis, and chondrocalcinosis within 6 months prior to screening, etc.);
  3. Presence of other diseases causing pain in the target knee (e.g., hip pain, lumbar spinal stenosis, intermittent claudication, etc.) or pain in other areas that, in the investigator's judgment, may affect the assessment of knee osteoarthritis pain;
  4. Use of other medications for osteoarthritis within 1 week prior to the first dose, such as NSAIDs (except aspirin ≤ 325 mg/day for cardiac prophylaxis), analgesics (except rescue acetaminophen used continuously for ≤ 3 days), symptomatic slow-acting drugs for osteoarthritis (diacerein, glucosamine, chondroitin sulfate, etc.), anxiolytics (doxepin, amitriptyline, pregabalin, etc.), or traditional Chinese medicines (containing active ingredients such as artificial tiger bone powder, Psammosilene tunicoides, etc.), whether oral or topical;
  5. The target knee has pathological joint effusion requiring aspiration or has surgical indications;
  6. Presence of chronic pain in other body parts requiring long-term oral analgesic therapy, or need for concomitant systemic therapy from 4 weeks prior to the first dose through the study period;
  7. Open knee injury or other knee surgeries (e.g., arthroscopy, arthroscopic debridement, knee replacement, etc.) on the target knee within 6 months prior to the first dose;
  8. Undergone any major surgical procedure within 3 months prior to the first dose;
  9. Received intra-articular injection therapy (e.g., corticosteroids or sodium hyaluronate, etc.) in the target knee within 3 months prior to the first dose;
  10. Received treatment with other drugs or devices within 4 weeks prior to the first dose;
  11. Received physical therapy (e.g., electrotherapy, etc.) for knee osteoarthritis in the target knee within 3 months prior to the first dose;
  12. Patients who are unable to ambulate independently and require assistive devices for more than 50% of ambulation time within 4 weeks prior to the first dose;
  13. Applied any capsaicin-containing products or NSAIDs to the skin of the target knee within 2 weeks prior to the first dose;
  14. History of allergy, , or intolerance to any component of the investigational product ASKC200 liniment, the comparator diclofenac diethylamine emulgel, or the rescue medication acetaminophen, or to any other NSAIDs;
  15. Presence of open wounds, skin erythema or edema, skin infection, or any other skin lesions on the target knee prior to the first dose that, in the investigator's opinion, may affect subject safety or absorption of the study drug;
  16. Instability of the target knee, such as cruciate ligament tear, ligamentous laxity, or significant valgus/varus deformity;
  17. History of gastrointestinal bleeding within 6 months prior to screening;
  18. Subjects planning to undergo surgery during the study period (including but not limited to general surgery, orthopedic surgery, gynecological/obstetric surgery, etc.);
  19. In the investigator's judgment, subjects have any unstable cardiovascular, cerebrovascular, respiratory, neurological, immunological, hematological, hepatic, renal, or endocrine systemic disease that remains uncontrolled despite standard treatment;
  20. Abnormal liver function tests (, aspartate aminotransferase, lactate dehydrogenase, total ≥ 1.5 × );
  21. Abnormal renal function tests (creatinine ≥ 1.5 × ULN);
  22. Clinically significant abnormalities on 12-lead that, in the investigator's judgment, preclude participation, including but not limited to prolonged interval (defined as > 450 ms in males or > 470 ms in females), second-degree or third-degree atrioventricular block;
  23. Subjects with uncontrolled hypertension without medication, or hypertension that remains uncontrolled despite medication (defined as systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg);
  24. History of within 5 years (excluding successfully treated non- cutaneous squamous cell carcinoma or basal cell carcinoma and/or cervical carcinoma in situ);
  25. History of alcohol or drug dependence within 12 months prior to the first dose;
  26. Psychiatric disorders that may affect the subject's ability to comply with study procedures or complete the study (including but not limited to a history of mania, bipolar disorder, schizophrenia, or schizoaffective disorder);
  27. Pregnant or breastfeeding women;
  28. Subjects deemed by the investigator to have poor compliance or other reasons that make them unsuitable for participation in this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    5% ASKC200

    Drug: 5% ASKC200 · Drug: Placebo

  • Active comparator
    1% Diclofenac Diethylamine Emulgel

    Drug: 1% Diclofenac Diethylamine Emulgel · Drug: Placebo

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    1% ASKC200

    Drug: Placebo · Drug: 1% ASKC200

Interventions

  • Drug5% ASKC200

    A single dose will be topically applied to study knees for 60 minutes on Visit 1 on Day 1, Day 2, Day 3, and Day 4.

  • Drug1% Diclofenac Diethylamine Emulgel

    Day 5-18;Four times daily

  • DrugPlacebo

    ASKC200 Placebo or Diclofenac Diethylamine Placebo

  • Drug1% ASKC200

    A single dose will be topically applied to study knees for 60 minutes on Visit 1 on Day 1, Day 2, Day 3, and Day 4.

06

What researchers measure

Primary outcomes

  1. Change in WAADPI (NRS) of the target knee from baseline

    The average amount of pain as reported by the subject using a 0 - 10 numerical rating scale (NRS). Higher scores indicate more pain.

    Time frame: Day 34

Secondary outcomes

  1. Change in WAADPI (NRS) of the target knee from baseline

    The average amount of pain as reported by the subject using a 0 - 10 numerical rating scale (NRS). Higher scores indicate more pain.

    Time frame: Day 19, Day 64,Day 94

  2. Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score

    The WOMAC Index is a questionnaire used to assess health status and health outcomes in KOA. The questionnaire contains 24 questions on pain, stiffness and physiology, will ask participants to complete the WOMAC questionnaire considering their symptoms in the past 48 hours.

    Time frame: Day 19,Day 34,Day 64,Day 94

  3. Change in patient's clinical general impression (PGIC)

    The change in patient\&#39;s clinical general impression as reported by the subject using a 0 - 7 scale (PGIC).

    Time frame: Day 19,Day 34 ,Day 64,Day 94

  4. Days of first-aid medicine administration

    Subjects will record their administration of first-aid medicine.

    Time frame: 94days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Apr 2026, 7 months.

Of 54 industry-sponsored phase 2 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 7 months is below that.

Counting every sponsor, half of 82 studies reached it within 19 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2026
First posted
Aug 3, 2026
StartActual
Sep 12, 2025
Primary completionActual
Apr 28, 2026
CompletionEst.
Sep 30, 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07742852
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Sep 12, 2025
Primary completion
Apr 28, 2026
Completion
Sep 30, 2026 (estimated)
Last update
Aug 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion